GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Ayala Pharmaceuticals Inc (STU:FAD) » Definitions » Dividend-Payout-to-FFO

Ayala Pharmaceuticals (STU:FAD) Dividend-Payout-to-FFO


View and export this data going back to 2023. Start your Free Trial

What is Ayala Pharmaceuticals Dividend-Payout-to-FFO?

Dividend-Payout-to-FFO only applies to REITs.


Ayala Pharmaceuticals (STU:FAD) Business Description

Traded in Other Exchanges
N/A
Address
Oppenheimer 4, Rehovot, ISR, 7670104
Ayala Pharmaceuticals Inc clinical-stage oncology company focused on developing and commercializing small molecule therapeutics for patients suffering from rare and aggressive cancers, primarily in genetically defined patient populations. The company's current portfolio of product candidates, AL101 and AL102, targets the aberrant activation of the Notch pathway with gamma-secretase inhibitors. Its product candidate, AL101, is being developed as a potent, selective, injectable small molecule gamma-secretase inhibitor, or GSI. It is also developing AL101 for the treatment of T-ALL, an aggressive, rare form of T-cell-specific leukemia.